Prognostic stratification in DLBCL patients with aberrant MYC gene
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19699 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Jian-Rong Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-myc. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease characterized by a subset of patients who exhibit treatment resistance and poor prognoses. Genomic assays have been widely employed to identify high‐risk individuals characterized by rearrangements in the MYC , BCL2 and BCL6 genes. These patients typically undergo more aggressive therapeutic treatments; however, there remains a significant variation in their treatment outcomes. This study introduces an MYC signature score (MYCSS) derived from gene expression profiles, specifically designed to evaluate MYC overactivation in DLBCL patients. MYCSS was validated across several independent cohorts to assess its ability to stratify patients based on MYC ‐related genetic and molecular aberrations, enhancing the accuracy of prognostic evaluations compared to conventional MYC biomarkers. Our results indicate that MYCSS significantly refines prognostic accuracy beyond that of conventional MYC biomarkers focused on genetic aberrations. More importantly, we found that nearly 50% of patients identified as high risk by traditional MYC metrics actually share similar survival prospects with those having no MYC aberrations. These patients may benefit from standard GCB‐based therapies rather than more aggressive treatments. MYCSS provides a robust signature that identifies high‐risk patients, aiding in the precision treatment of DLBCL, and minimizing the potential for overtreatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
- Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
ORCID-Profile: Chao Cheng
Förderung
- NCI NIH HHS
- NIH HHS
- Cancer Prevention and Research Institute of Texas
- Center for Biomedical Informatics and Information Technology
Zitieren
APA
Li, J. R., Shaw, V. R., Parthasarathy, A., Li, Y., Amos, C. I., & Cheng, C. (2024). Prognostic stratification in DLBCL patients with aberrant MYC gene. British Journal of Haematology. https://doi.org/10.1111/bjh.19699
Vancouver
Li JR, Shaw VR, Parthasarathy A, Li Y, Amos CI, Cheng C. Prognostic stratification in DLBCL patients with aberrant MYC gene. British Journal of Haematology. 2024. doi:10.1111/bjh.19699
BibTeX
@article{Li2024,
author = {Li, Jian-Rong and Shaw, Vikram R and Parthasarathy, Abi and Li, Yong and Amos, Christopher I and Cheng, Chao},
title = {Prognostic stratification in DLBCL patients with aberrant MYC gene},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19699}
}
EUVIMED